<DOC>
	<DOCNO>NCT01391104</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) characterize progressive increase pulmonary vascular resistance lead shortness breath exercise intolerance . Exercise capacity use primary endpoint recent randomize controlled trial evaluate PAH-specific therapy correlate functional class survival PAH . Exercise test commonly assess six-minute walk test ( 6MWT ) . However , commonly discrepancy significant clinical improvement minor change ( generally &lt; 10 % baseline ) 6WMT follow therapy . Because important clinical decision base patient ' functional capacity , reproducible sensitive exercise test need PAH . The aim study compare reproducibility responsiveness 6MWT , endurance shuttle walk test ( ESWT ) cycle endurance test ( CET ) follow pharmacological therapy disease .</brief_summary>
	<brief_title>Responsiveness Exercise Tests Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>WHO functional class II III Idiopathic PAH , familial PAH , associate PAH due connective tissue disease patient Mean pulmonary artery pressure ≥25 mmHg rest Pulmonary capillary wedge pressure ≤15 mmHg Prior use phosphodiesterase type5 inhibitor Unstable clinical condition last 4 month Recent syncope WHO functional class IV Left ventricular ejection fraction &lt; 40 % Restrictive obstructive lung disease Intrinsic musculoskeletal abnormality preclude exercise test Patients pacemaker Treatment systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Exercise</keyword>
	<keyword>Six-minute walk test</keyword>
	<keyword>sildenafil</keyword>
</DOC>